NJ Bio, Inc., a provider of drug discovery and development services, and Ajinomoto Bio‑Pharma Services (Aji Bio‑Pharma), a provider of biopharmaceutical manufacturing services and platform technologies, entered research collaboration to expand access to AJICAP, Aji Bio‑Pharma’s site‑specific conjugation platform for NJ Bio’s discovery‑stage and early development clients. 

This collaboration broadens NJ Bio’s antibody conjugation and linker capabilities to support the development of next‑gen antibody–drug conjugates (ADCs) and other targeted therapeutics. 

NJ Bio will integrate the AJICAP platform into its discovery and development workflows, offering clients a robust and highly reproducible approach for site‑specific conjugation of cytotoxic and non‑cytotoxic payloads to antibodies. AJICAP is designed to enable precise chemical modification at defined lysine residues without the need for antibody engineering, preserving antibody structure and functionality while improving pharmacokinetics, therapeutic index, and overall developability. 

The platform supports a range of stable, hydrophilic linker systems and is readily incorporated into drug discovery and development programs. 

Clients will have access to NJ Bio’s expertise in medicinal chemistry, bioconjugation, and biologics development, combined with the precision, reproducibility, and flexibility of the AJICAP platform. NJ Bio anticipates that this collaboration will help reduce development risk, shorten timelines, and improve overall project outcomes. 

“Expanding our capabilities with AJICAP aligns strongly with NJ Bio’s mission to deliver cutting-edge, high-value solutions that accelerate our clients’ discovery programs,” said Julien Dugal-Tessier, the President and Chief Scientific Officer at NJ Bio. “This collaboration enables us to offer a proven, scalable site-specific conjugation platform, expand access to AJICAP capabilities, and support the development of novel antibody-based medicines with improved efficacy and safety profiles.” 

“AJICAP was developed to enable precise and scalable antibody conjugation, and we are excited to extend its reach through this collaboration with NJ Bio,” said Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Dept., Ajinomoto Co., Inc. “Together, we are enhancing the tools available to biopharma innovators to design and develop next-generation targeted therapies for patients.”